Literature DB >> 1737777

High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. Molecular characterization and cellular distribution.

A Godard1, D Heymann, S Raher, I Anegon, M A Peyrat, B Le Mauff, E Mouray, M Gregoire, K Virdee, J P Soulillou.   

Abstract

Radioiodinated recombinant human interleukin DA (HILDA)/leukemia inhibitory factor (LIF) purified from conditioned medium of Chinese hamster ovary transfected cells enabled the identification of specific receptor sites on a variety of human cell types. Using low concentrations (up to 500 pM) of the ligand iodinated at a high specific radioactivity, high affinity receptors (equilibrium dissociation constant Kd in the range of 30-100 pM) were first demonstrated. They were expressed at low levels by human peripheral blood monocytes but not by lymphocytes, NK cells, granulocytes, and platelets. The myelomonocytic cell line THP1 as well as the T lymphoma cell line HSB2 and the lymphoblastoid B cell line DAB were also receptor-negative. In contrast, most of the non-lymphoid tumoral cell lines tested, including melanomas, neuroblastomas, and carcinomas, expressed high affinity HILDA/LIF receptors at variable levels (Bmax from 20 to 600 sites/cell). The kinetics of HILDA/LIF high affinity binding to the choriocarcinoma JAR cell line were characterized at 4 degrees C with association and dissociation rate constants of k1 = 2.2 10(9) M-1 min-1 and k-1 = 0.0084 min-1, respectively, corresponding to a steady-state dissociation constant k1/k-1 = 3.8 pM. The subsequent use of higher concentrations of HILDA/LIF labeled at a lower specific radioactivity enabled the identification of a low affinity component on several cell lines (Kd in the range of 1-4 nM; Bmax from 1,000 to 5,000 sites/cell). On JAR cells, this low affinity component was characterized by association and dissociation rate constants at 4 degrees C of k1 = 7.3 10(7) M-1 min-1 and k-1 = 0.19 min-1, respectively (k-1/k1 = 2.6 nM). Affinity cross-linking of HILDA/LIF to JAR cells showed two cross-linked species under both reducing and nonreducing conditions corresponding to receptor species of 120 and 250 kDa, respectively. Whereas both bands had similar intensities under high affinity conditions, the higher band predominated under low affinity conditions. Our data suggest that the 250-kDa chain could constitute the low affinity binding component whereas the association of both 250- and 120-Da subunits would form the high affinity structure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737777

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Establishment of a long-term culture system for rat colon epithelial cells.

Authors:  Ingrid Bartsch; Ingrid Zschaler; Monika Haseloff; Pablo Steinberg
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Sep-Oct       Impact factor: 2.416

Review 2.  Activating mechanism of CNTF and related cytokines.

Authors:  M Inoue; C Nakayama; H Noguchi
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

3.  Extensive mannose phosphorylation on leukemia inhibitory factor (LIF) controls its extracellular levels by multiple mechanisms.

Authors:  Jarrod Barnes; Jae-Min Lim; Anne Godard; Frédéric Blanchard; Lance Wells; Richard Steet
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

4.  CNTF and its receptor subunits in human gliomas.

Authors:  J Weis; L M Schönrock; S L Züchner; D C Lie; U Sure; C Schul; F Stögbauer; E B Ringelstein; H Halfter
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids.

Authors:  P Waring; K Wycherley; D Cary; N Nicola; D Metcalf
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF.

Authors:  Q L Li; H Yano; S G Ren; X Li; T C Friedman; S Melmed
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

7.  Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome.

Authors:  Nathalie Dagoneau; Deborah Scheffer; Céline Huber; Lihadh I Al-Gazali; Maja Di Rocco; Anne Godard; Jelena Martinovic; Annick Raas-Rothschild; Sabine Sigaudy; Sheila Unger; Sophie Nicole; Bertrand Fontaine; Jean-Luc Taupin; Jean-François Moreau; Andrea Superti-Furga; Martine Le Merrer; Jacky Bonaventure; Arnold Munnich; Laurence Legeai-Mallet; Valérie Cormier-Daire
Journal:  Am J Hum Genet       Date:  2004-01-21       Impact factor: 11.025

8.  Characterization of a binding protein for leukemia inhibitory factor localized in extracellular matrix.

Authors:  A Mereau; L Grey; C Piquet-Pellorce; J K Heath
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

9.  In Vitro Maturation with Leukemia Inhibitory Factor Prior to the Vitrification of Bovine Oocytes Improves Their Embryo Developmental Potential and Gene Expression in Oocytes and Embryos.

Authors:  Meritxell Vendrell-Flotats; Tania García-Martínez; Iris Martínez-Rodero; Manel Lopez-Bejar; Jonathan LaMarre; Marc Yeste; Teresa Mogas
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.